anti-CD20/anti-CD22 CAR T cells
Term · Oncology and biomedicine · MLC-T-ONC-010297
A preparation of human T lymphocytes engineered to express chimeric antigen receptors (CARs) specific for the tumor-associated antigens (TAAs) cluster of differentiation 20 (CD20) and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD20/anti-CD22 CAR T cells target and bind to both CD20 and CD22 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. CD20 and CD22 are overexpressed in certain hematologic malignancies.
| Identifier | MLC-T-ONC-010297 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | CD20/CD22-targeted CAR T cells; CD20/CD22 dual targeted CAR T cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010297",
"term": "anti-CD20/anti-CD22 CAR T cells",
"field": "Oncology and biomedicine",
"definition": "A preparation of human T lymphocytes engineered to express chimeric antigen receptors (CARs) specific for the tumor-associated antigens (TAAs) cluster of differentiation 20 (CD20) and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD20/anti-CD22 CAR T cells target and bind to both CD20 and CD22 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. CD20 and CD22 are overexpressed in certain hematologic malignancies.",
"synonyms": [
"CD20/CD22-targeted CAR T cells",
"CD20/CD22 dual targeted CAR T cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-cd20-anti-cd22-car-t-cells/"
}
Record 1,383 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.